Why Do Some Cancer Patients Respond Remarkably Well While Others Face Setbacks?
The answer lies in the unique biological profile of each patient’s tumour — RGCC Onconomics Plus® can read it with precision
Clinical Reality: Identical Diagnoses, Dramatically Different Outcomes
The same non-small-cell lung cancer: why do some patients remain stable on osimertinib for over a year while others develop resistance within months? Triple-negative breast cancer: why do some complete standard chemotherapy with tolerable side effects while others require dose reductions due to severe myelosuppression? Metastatic colorectal cancer: why do certain individuals achieve long-term disease control when specific natural compounds are added, while others see no benefit? The fundamental reason is that every tumour has its own distinct molecular drivers, resistance mechanisms, and sensitivity patterns to both conventional drugs and natural agents.
Limitations of Conventional Treatment Strategies
Pathological classification and genomic testing have advanced significantly, yet they provide essentially static information. They cannot capture the dynamic molecular changes and escape pathways that tumours develop during treatment. The common “trial-and-observe-adjust” approach often means patients first endure ineffective therapies and their associated toxicities.
Where the True Tumour “Personality” Is Revealed
The most accurate answers come from direct functional testing of circulating tumour cells (CTCs) and their microenvironment in real time. Only this approach reveals the tumour’s current vulnerabilities and preferred resistance strategies.
RGCC Onconomics Plus®: The Most Comprehensive Individualised Data Available Today
A single peripheral blood draw, analysed in the internationally recognised RGCC laboratories in Greece, provides:
- Real sensitivity and resistance profile against 50+ conventional chemotherapeutic, targeted, and immunotherapeutic agents
- Inhibitory efficacy against 30+ rigorously validated natural compounds (curcumin, Reishi polysaccharide, silymarin, quercetin, high-dose vitamin C, etc.)
- Dominant oncogenic signalling pathways currently driving growth and metastasis
- Clear identification of ineffective or low-efficacy drugs, avoiding unnecessary toxicity
- Selection of natural agents showing high activity against the patient’s specific tumour, enhancing overall treatment benefit
From Population-Based Guidelines to True Personalised Precision Oncology
When the treating physician has your tumour’s bespoke sensitivity map, the most effective drug combinations and dosages can be selected from the outset, with proactive adjustments made before progression, maximising disease control while minimising avoidable side effects.
Summary
Differences in treatment outcomes ultimately stem from inter-patient tumour biological heterogeneity. RGCC Onconomics Plus® shifts clinical decision-making from statistical probability to laboratory-measured individual tumour response — the direction universally recognised by leading international oncology centres as genuine precision medicine.
If you wish to know the exact sensitivity profile of your tumour to both conventional and natural agents, please feel welcome to contact us. We will arrange RGCC Onconomics Plus® testing followed by a detailed one-to-one specialist interpretation.
Every patient deserves a treatment strategy built entirely around their own tumour — not merely a protocol designed for the majority.
Disclaimer：
The information provided in this article is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, nor should it replace professional medical advice. Readers are encouraged to consult with a qualified healthcare provider or integrative oncology specialist before making any changes to their diet, treatment plan, or lifestyle based on the content herein. Therapies and tests mentioned, including immune or integrative treatments, should always be…
All product names, test references, and therapy mentions are for informational context only and do not constitute endorsement. Results and experiences may vary among individuals.